Replies to post #2479 on Lisata Therapeutics Inc (LSTA)

[lunatick]

Oh Thank you very much for your work, great found and great article.
I think this is also interessting.
I found this at the website of PCT

"KITE PHARMA RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR KTE-C19, KITE'S LEAD CANCER T-CELL IMMUNOTHERAPY
Santa Monica, Calif., Sept. 11, 2015 -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 for designation as an orphan medicinal product for the treatment of PMBCL and MCL. KTE-C19 is an investigational therapy in which a patient's T cells are genetically engineered to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. No other product candidate currently has orphan drug designation for the treatment of PMBCL in the EU. Kite previously received orphan drug designation for KTE-C19 for the treatment of diffuse large B-cell lymphoma (DLBCL) in both the US and the EU.

"The positive opinion for EU orphan designation for PMBCL and for MCL aligns with Kite's leadership in and broad commitment to delivering innovative therapies that have the potential to transform the lives of cancer patients around the world," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite...."

http://www.pctcaladrius.com/industry-news/kite-pharma-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for-kte-c19-kites-lead-cancer-t-cell-immunotherapy
full press release
http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=931219

I think it's interessting because

"New York (April 20, 2015) — NeoStem, Inc. (NASDAQ:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, Inc. (NASDAQ:KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer...."

full press release: http://www.caladrius.com/press-release/neostem-announces-expanded-cell-therapy-manufacturing-relationship-with-kite-pharma/

I think there is a lot going on in the background.
But this is only my opinion.